Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 8, 2026, 5:42 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 237 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Olanzapine/Zyprexa Clear all
Completed Phase 1 Interventional Results available

Indenoisoquinoline LMP744 in Adults With Relapsed Solid Tumors and Lymphomas

NCT03030417
View directory record Official record
Conditions
Solid Tumors, Lymphoma
Interventions
LMP744, Ondansetron, Olanzapine, Lorazepam, Diphenoxylate hydrocholoride (HCL) + Atropine Sulfate, Loperamide, Diphenhydramine, Steroid, Epinephrine
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
2
States / cities
Bethesda, Maryland • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 10, 2024 · Synced Oct 8, 2026, 5:42 AM EDT
Completed Not applicable Interventional Results available

Melatonin Metabolism Abnormality in Patients With Schizophrenia or Schizoaffective Disorder Treated With Olanzapine

NCT00512070
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Bipolar Disorder, Obesity, Metabolic Syndrome
Interventions
olanzapine and melatonin
Drug
Lead sponsor
Seattle Institute for Biomedical and Clinical Research
Other
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2024
U.S. locations
1
States / cities
Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Jan 1, 2025 · Synced Oct 8, 2026, 5:42 AM EDT
Completed No phase listed Observational

Family Intervention in Recent Onset Schizophrenia Treatment (FIRST)

NCT02600741
View directory record Official record
Conditions
Schizophrenia
Interventions
Caregiver psycho-education and skills training, Caregiver support available at the study site, Paliperidone palmitate, Chlorpromazine, Droperidol, Fluphenazine, Haloperidol, Loxapine, Perphenazine, Pimozide, Prochlorperazine, Thiothixene, Thioridazine, Trifluoperazine, Aripiprazole, Asenapine, Clozapine, Iloperidone, Olanzapine, Paliperidone, Quetiapine, Risperidone, Ziprasidone
Other · Drug
Lead sponsor
Janssen Scientific Affairs, LLC
Industry
Eligibility
18 Years and older
Enrollment
296 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
34
States / cities
Bullhead City, Arizona • Oceanside, California • Denver, Colorado + 31 more
Source: ClinicalTrials.gov public record
Updated Jan 23, 2019 · Synced Oct 8, 2026, 5:42 AM EDT
Completed Phase 2 Interventional Results available

A Study of ALKS 3831 in Subjects With Schizophrenia and Alcohol Use Disorder

NCT02161718
View directory record Official record
Conditions
Schizophrenia, Alcohol Use Disorder
Interventions
Samidorphan + olanzapine (ALKS 3831), Placebo + olanzapine
Drug
Lead sponsor
Alkermes, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
58
States / cities
Little Rock, Arkansas • Springdale, Arkansas • Anaheim, California + 50 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2021 · Synced Oct 8, 2026, 5:42 AM EDT
Completed Phase 4 Interventional Results available

NMDA Antagonists in Bipolar Depression

NCT01833897
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Standard of Care, Ketamine, D-cycloserine
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 60 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 1, 2016 · Synced Oct 8, 2026, 5:42 AM EDT
Terminated Phase 2 Interventional

Olanzapine Given in Combination With Zonisamide SR to Prevent Weight Gain in Schizophrenic Subjects

NCT00734435
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder
Interventions
zonisamide SR plus olanzapine, Placebo plus olanzapine
Drug
Lead sponsor
Orexigen Therapeutics, Inc
Industry
Eligibility
18 Years to 55 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
9
States / cities
National City, California • Orange, California • San Diego, California + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 29, 2012 · Synced Oct 8, 2026, 5:42 AM EDT
Completed Phase 2 Interventional Results available

Olanzapine for Nausea After Surgery

NCT02755116
View directory record Official record
Conditions
Postoperative Nausea and Vomiting
Interventions
Olanzapine, Placebo
Drug
Lead sponsor
Jaime B Hyman
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 27, 2020 · Synced Oct 8, 2026, 5:42 AM EDT
Completed Phase 4 Interventional Results available

15 Month Study for Adults Who Have Been Diagnosed With Schizophrenia and Incarcerated

NCT01157351
View directory record Official record
Conditions
Schizophrenia
Interventions
paliperidone, risperidone, haloperidole, perphenazine, aripiprazole, quetiapine, paliperidone palmitate, olanzapine
Drug
Lead sponsor
Janssen Scientific Affairs, LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
55
States / cities
Bullhead City, Arizona • Tuscon, Arizona • Little Rock, Arkansas + 52 more
Source: ClinicalTrials.gov public record
Updated Apr 24, 2015 · Synced Oct 8, 2026, 5:42 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

National Pregnancy Registry for Psychiatric Medications

NCT01246765
View directory record Official record
Conditions
Pregnant Women, Psychotropic Drugs
Interventions
Not listed
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
5,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2033
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 24, 2025 · Synced Oct 8, 2026, 5:42 AM EDT
Terminated No phase listed Observational

Longitudinal Comparative Effectiveness of Bipolar Disorder Therapies

NCT02893371
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Lithium Carbonate, Lamotrigine, Valproic Acid, Oxcarbazepine, Carbamazepine, Ziprasidone, Risperidone, Quetiapine, Olanzapine, Aripiprazole, Fluoxetine / Olanzapine, Haloperidol, Perphenazine, Clozapine, Asenapine, Lurasidone, Paliperidone, Mirtazapine, Bupropion, Desvenlafaxine, Duloxetine, Venlafaxine, Citalopram, Escitalopram, Fluoxetine, Fluvoxamine, Paroxetine, Sertraline, Vilazodone, Doxepin
Drug
Lead sponsor
University of New Mexico
Other
Eligibility
Not listed
Enrollment
1,037,352 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Mar 12, 2024 · Synced Oct 8, 2026, 5:42 AM EDT
Completed Phase 4 Interventional

The Assessment of a Weight-Gain Agent for the Treatment of Olanzapine-Associated Anti-Obesity Agent in Patients With Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder, and Bipolar I Disorder

NCT00044187
View directory record Official record
Conditions
Schizophrenia, Psychotic Disorders, Bipolar Disorder
Interventions
Sibutramine
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
16
States / cities
El Centro, California • Jacksonville, Florida • Miami, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2006 · Synced Oct 8, 2026, 5:42 AM EDT
Completed Phase 4 Interventional Results available

Atomoxetine for Treatment of Weight Gain in Olanzapine or Clozapine Patients

NCT00176436
View directory record Official record
Conditions
Schizophrenia
Interventions
Diet support group, Group counseling and exercise
Behavioral
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Catonsville, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 14, 2022 · Synced Oct 8, 2026, 5:42 AM EDT
Completed Phase 2 Interventional Results available

Use of Galantamine and CDP-choline (Citicoline) to Treat Adults With Schizophrenia

NCT00509067
View directory record Official record
Conditions
Schizophrenia
Interventions
Galantamine, CDP-choline, Placebo, risperidone, olanzapine, quetiapine, ziprasidone, and/or aripiprazole
Drug
Lead sponsor
Georgetown University
Other
Eligibility
18 Years to 70 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Apr 11, 2018 · Synced Oct 8, 2026, 5:42 AM EDT
Recruiting Phase 3 Interventional

Study to Evaluate Weight Gain as Assessed by Change in BMI Z-score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder

NCT05303064
View directory record Official record
Conditions
Schizophrenia, Bipolar I Disorder
Interventions
OLZ/SAM, Olanzapine
Drug
Lead sponsor
Alkermes, Inc.
Industry
Eligibility
10 Years to 17 Years
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
26
States / cities
Dothan, Alabama • Little Rock, Arkansas • Encino, California + 23 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2026 · Synced Oct 8, 2026, 5:42 AM EDT
Completed Phase 4 Interventional

Study of Olanzapine vs. Aripiprazole in the Treatment of Schizophrenia

NCT00088049
View directory record Official record
Conditions
Schizophrenia
Interventions
Olanzapine, Aripiprazole
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
560 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
24
States / cities
Little Rock, Arkansas • Garden Grove, California • National City, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2007 · Synced Oct 8, 2026, 5:42 AM EDT
Completed Phase 3 Interventional Results available

A Randomized, Double-Blind, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy and Safety of TV-44749 in Adults With Schizophrenia

NCT05693935
View directory record Official record
Conditions
Schizophrenia
Interventions
TV-44749, Placebo
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D LLC
Industry
Eligibility
18 Years to 64 Years
Enrollment
675 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
53
States / cities
Bentonville, Arkansas • Little Rock, Arkansas • Rogers, Arkansas + 38 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2026 · Synced Oct 8, 2026, 5:42 AM EDT
Completed Phase 3 Interventional

Study Comparing the Affect of Bifeprunox Vs Olanzapine on Weight During the Treatment of Outpatients With Schizophrenia.

NCT00380224
View directory record Official record
Conditions
Schizophrenia
Interventions
bifeprunox, olanzapine
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
67
States / cities
Little Rock, Arkansas • Anaheim, California • Boynton Beach, California + 55 more
Source: ClinicalTrials.gov public record
Updated Dec 27, 2007 · Synced Oct 8, 2026, 5:42 AM EDT
Completed Phase 4 Interventional Results available

Exenatide for the Treatment of Weight Gain Associated With Olanzapine in Obese Adults

NCT00845507
View directory record Official record
Conditions
Weight Gain
Interventions
Exenatide, Placebo
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years to 55 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 20, 2018 · Synced Oct 8, 2026, 5:42 AM EDT
Completed Phase 3 Interventional Results available

Effect of Lu AF35700 in Patients With Treatment-resistant Schizophrenia

NCT02717195
View directory record Official record
Conditions
Schizophrenia
Interventions
Risperidone, Olanzapine, Lu AF35700
Drug
Lead sponsor
H. Lundbeck A/S
Industry
Eligibility
18 Years and older
Enrollment
1,098 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
49
States / cities
Bellflower, California • Cerritos, California • Costa Mesa, California + 39 more
Source: ClinicalTrials.gov public record
Updated Nov 25, 2019 · Synced Oct 8, 2026, 5:42 AM EDT
Completed Phase 2Phase 3 Interventional

Long-Term Olanzapine Treatment in Children With Autism

NCT00183404
View directory record Official record
Conditions
Autism
Interventions
Olanzapine
Drug
Lead sponsor
Drexel University
Other
Eligibility
3 Years to 12 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2011
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 15, 2014 · Synced Oct 8, 2026, 5:42 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Olanzapine for Acute Headaches

NCT03066622
View directory record Official record
Conditions
Headache
Interventions
Standard of Care as per attending physician, 5mg rapidly dissolving olanzapine
Drug
Lead sponsor
HealthPartners Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
122 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 12, 2022 · Synced Oct 8, 2026, 5:42 AM EDT
Active, not recruiting Phase 1 Interventional Results available

Selinexor (KPT-330) in Combination With Temozolomide and Radiation Therapy in Patients With Newly Diagnosed Glioblastoma

NCT04216329
View directory record Official record
Conditions
Gliosarcoma, Newly Diagnosed, Glioblastoma
Interventions
Selinexor, Temozolomide, Generic Radiation therapy (RT), Selective serotonin receptor (5-HT3) antagonists, Olanzapine, Salt tablets, Anti-diarrheal
Drug · Radiation · Other + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 23, 2026 · Synced Oct 8, 2026, 5:42 AM EDT
Completed Phase 3 Interventional Results available

A Study of ALKS 3831 in Adults With Acute Exacerbation of Schizophrenia (the ENLIGHTEN-1 Study)

NCT02634346
View directory record Official record
Conditions
Schizophrenia
Interventions
ALK3831, Olanzapine, Placebo
Drug
Lead sponsor
Alkermes, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
403 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
16
States / cities
Little Rock, Arkansas • Springdale, Arkansas • Culver City, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2018 · Synced Oct 8, 2026, 5:42 AM EDT
Completed Phase 4 Interventional

Large Simple Trial (LST) Of Cardiovascular Safety Of Ziprasidone And Olanzapine- (Zodiac)

NCT00418171
View directory record Official record
Conditions
Schizophrenia
Interventions
Ziprasidone, Olanzapine
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
18,239 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
5
States / cities
San Bernardino, California • ‘Aiea, Hawaii • Schaumburg, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2009 · Synced Oct 8, 2026, 5:42 AM EDT